Company
Kinasettherapeutics
Developing inhaled therapeutics in respiratory diseases
Also known as Kinaset, Kinaset Therapeutics
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- Kinaset Therapeutics
- kinasettherapeutics.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 29 September 2026
About
Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. Our lead clinical candidate, frevecitinib (KN-002), is a novel and non-invasive anti-inflammatory to treat all patients with severe asthma. With our founding investors, 5AM Ventures, Atlas Venture and Gimv, we are pursuing a patient-focused approach to build a leading respiratory therapeutics company.
Funding snapshot
- Total raised
- $143MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series B, $103M2026-01-10
Funding rounds
- Series B
- $103M2026-01-10, Company stated
- Round, 2022
- $28.5M2022-07-05, SEC form D sold, 3 investors
- Series A
- $40M2020-11-30, Company stated
- Round, 2020
- $1.5M2020-07-31, SEC form D sold, 3 investors
Products
- Web
- frevecitinib (KN-002)
Loading relationship preview